‘The Top Line’: Gene editing’s next act
Gene editing’s therapeutic application has transitioned from hypothetical to reality, marked by the recent approval of a CRISPR-based therapy for sickle cell and beta thalassemia. | This week on “The Top Line,” Max Bayer from Fierce Biotech explores the future of gene editing in an interview with the CEO of Verve Therapeutics.